Close Menu

NEW YORK – Sight Diagnostics of Israel said on Wednesday that it has raised $71 million in Series D funding, bringing its total funding to date to more than $124 million.

Koch Disruptive Technologies, Longliv Ventures, and OurCrowd participated in the round.

The company, based in Tel Aviv, said it will use the new funding to support the expansion of its commercial operations globally and advance its R&D into the detection of new diseases as well as blood factors affecting COVID-19 severity.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.